2019, 2020, 2021
The Amylyx PEGASUS Alzheimer’s disease phase 2 clinical trial will enroll 100 patients in sites across the country in a double-blind protocol to test a combination therapy. AMX0035 is composed of two known compounds that together address endoplasmic reticulum and mitochondrial stress, both of which have been implicated in neuronal death and degradation. The trial is enrolling patients who already are experiencing mild cognitive impairment or early dementia. Readout is anticipated in 2021.